In the United States, the marketing approval does not contain these restrictions, though the label contains prominent warnings of skin reactions. The initial approval by the Food and Drug Administration of the United States (December 1999) encompassed these indications:

Acute exacerbations of chronic bronchitis
Acute bacterial sinusitis
Community acquired pneumoniaAdditional indications approved by the Food and Drug Administration:

April 2001: Uncomplicated skin and skin-structure infections
May 2004: Community-acquired pneumonia caused by multidrug-resistant Streptococcus pneumoniae
June 2005: Complicated skin and skin-structure infections
November 2005: Complicated intra-abdominal infectionsThe European Medicines Agency has advised that, for pneumonia, acute bacterial sinusitis, and acute exacerbations of COPD, it should only be used when other antibiotics are inappropriate.Oral and intravenous moxifloxacin have not been approved for children. Several drugs in this class, including moxifloxacin, are not licensed by the Food and Drug Administration for use in children, because of the risk of permanent injury to the musculoskeletal system. Moxifloxacin eye drops are approved for conjunctival infections caused by susceptible bacteria.Recently, alarming reports of moxifloxacin resistance rates among anaerobes have been published. In Austria 36% of Bacteroides have been reported to be reistant to moxifloxacin, while in Italy resistance rates as high as 41% have been reported. Susceptible bacteria
A broad spectrum of bacteria is susceptible, including the following:

Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Haemophilus influenzae
Klebsiella spp. Moraxella catarrhalis
Enterobacter spp. Mycobacterium spp.
Regular insulin, lispro, aspart and glulisine can be used for this purpose. Regular insulin should be given with about a 30-minute lead-time prior to the meal to be maximally effective and to minimize the possibility of hypoglycemia. Lispro, aspart and glulisine are approved for dosage with the first bite of the meal, and may even be effective if given after completing the meal. The short-acting insulin is also used to correct hyperglycemia.The usual schedule for checking fingerstick blood glucose and administering insulin is before all meals and sometimes also at bedtime. More recent guidelines also call for a check 2 hours after a meal to ensure the meal has been covered effectively. Sliding scales
First described in 1934, what physicians typically refer to as sliding-scale insulin (SSI) is fast- or rapid-acting insulin only, given subcutaneously, typically at meal times and sometimes bedtime, but only when blood glucose is above a threshold (e.g. 10 mmol/L, 180 mg/dL). The so-called "sliding-scale" method is widely taught, although it has been heavily criticized. Sliding scale insulin (SSI) is not an effective way of managing long-term diabetes in individuals residing in nursing homes. Sliding scale insulin leads to greater discomfort and increased nursing time. Sample regimen using insulin glargine and insulin lispro:

Insulin glargine: 20 units at bedtime

Carb counting and DAFNE
A more complicated method that allows greater freedom with meal times and snacks is "carb counting." This approach is taught to people who are diabetic in the UK and elsewhere as "Dose Adjustment For Normal Eating" or DAFNE.